The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Polymyxins Revisited
Open accessAbstract
SUMMARY: The global emergence of multidrug-resistant gram-negative bacilli has spurred a renewed interest in polymyxins. Once discarded due to concerns regarding nephrotoxicity and neurotoxicity, polymyxins now hold an important role in the antibiotic armamentarium. However, more reliable information is needed to determine the optimal dosing of these agents. Also, unanswered questions regarding in vitro testing remain, including questions regarding the reliability of automated systems and the establishment of appropriate breakpoints for defining susceptibility. Most contemporary clinical studies examining the use of these agents have involved patients with infections due to multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii strains. It has been reassuring that polymyxin therapy for resistant bacteria has resulted in clinical responses and toxicity rates similar to those for carbapenem therapy for susceptible isolates. While most surveillance studies demonstrated high rates of susceptibility, several reports noted the emergence of polymyxin-resistant nosocomial pathogens. Polymyxins have assumed an important antibiotic niche for therapy for hospital-acquired infections; further studies defining the optimal use of these agents will likely extend the duration of their clinical usefulness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
Zavascki, A. P., Goldani, L. Z., Li, J., & Nation, R. L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm357 · Cited by 834
Levin, A. S., Barone, A. A., Penço, J., Santos, M. V., Marinho, I. S., Arruda, E. A. G., Manrique, E. I., & Costa, S. F. (1999) · Clinical Infectious Diseases · doi:10.1086/514732 · Cited by 612
Bratu, S., Landman, D., Haag, R., Recco, R., Eramo, A., Alam, M., & Quale, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1430 · Cited by 573
Self-citationEvaluation of colistin as an agent against multi-resistant Gram-negative bacteria
Li, J., Nation, R. L., Milne, R. W., Turnidge, J. D., & Coulthard, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.10.001 · Cited by 571
Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii
Li, J., Rayner, C. R., Nation, R. L., Owen, R. J., Spelman, D., Tan, K. E., & Liolios, L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00103-06 · Cited by 548
Polymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria
Evans, M. E., Feola, D. J., & Rapp, R. P. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18426 · Cited by 544
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
Valerius, N. H., Koch, C., & Høiby, N. (1991) · The Lancet · doi:10.1016/0140-6736(91)91446-2 · Cited by 475
Garnacho‐Montero, J., Ortiz‐Leyba, C., Jimenez‐Jimenez, F. J., Barrero‐Almodovar, A. E., Garcia‐Garmendia, J. L., Bernabeu‐WittelI, M., Gallego‐Lara, S. L., & Madrazo‐Osuna, J. (2003) · Clinical Infectious Diseases · doi:10.1086/374337 · Cited by 470
Gales, A. C., Reis, A. O., & Jones, R. N. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.1.183-190.2001 · Cited by 382
Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa
Bergen, P. J., Li, J., Rayner, C. R., & Nation, R. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00035-06 · Cited by 366
Jensen, T., Pedersen, S. S., Garne, S., Heilmann, C., Høiby, N., & Koch, C. (1987) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/19.6.831 · Cited by 314
Manikal, V. M., Landman, D., Saurina, G., Oydna, E., Lal, H., & Quale, J. (2000) · Clinical Infectious Diseases · doi:10.1086/313902 · Cited by 309
Self-citationBratu, S., Tolaney, P., Karumudi, U., Quale, J., Mooty, M., Nichani, S., & Landman, D. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki175 · Cited by 307
Self-citationGales, A. C., Jones, R. N., & Sader, H. S. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01351.x · Cited by 302
Michalopoulos, A. S., Tsiodras, S., Rellos, K., Mentzelopoulos, S., & Falagas, M. E. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.01043.x · Cited by 292
Regulation of polymyxin resistance and adaptation to low-Mg2+ environments
Groisman, E. A., Kayser, J., & Soncini, F. C. (1997) · Journal of Bacteriology · doi:10.1128/jb.179.22.7040-7045.1997 · Cited by 282
Markou, N., Apostolakos, H., Koumoudiou, C., Athanasiou, M., Koutsoukou, A., Alamanos, I., & Gregorakos, L. (2003) · Critical Care · doi:10.1186/cc2358 · Cited by 278
Antoniadou, A., Kontopidou, F., Poulakou, G., Koratzanis, E., Galani, I., Papadomichelakis, E., Kopterides, P., Souli, M., Armaganidis, A., & Giamarellou, H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl562 · Cited by 273
Ko, K. S., Suh, J. Y., Kwon, K. T., Jung, S.-I., Park, K.-H., Kang, C. I., Chung, D. R., Peck, K. R., & Song, J.-H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm305 · Cited by 262
Linden, P. K., Kusne, S., Coley, K., Fontes, P., Kramer, D. J., & Paterson, D. (2003) · Clinical Infectious Diseases · doi:10.1086/379611 · Cited by 252
Bratu, S., Mooty, M., Nichani, S., Landman, D., Gullans, C., Pettinato, B., Karumudi, U., Tolaney, P., & Quale, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.3018-3020.2005 · Cited by 246
Self-citationLo-Ten-Foe, J. R., de Smet, A. M. G. A., Diederen, B. M. W., Kluytmans, J. A. J. W., & van Keulen, P. H. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01406-06 · Cited by 242
Toxicity after prolonged (more than four weeks) administration of intravenous colistin
Falagas, M. E., Rizos, M., Bliziotis, I. A., Rellos, K., Kasiakou, S. K., & Michalopoulos, A. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-1 · Cited by 242
Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria
Falagas, M. E., Bliziotis, I. A., Kasiakou, S. K., Samonis, G., Athanassopoulou, P., & Michalopoulos, A. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-24 · Cited by 224
Michalopoulos, A., Kasiakou, S. K., Mastora, Z., Rellos, K., Kapaskelis, A. M., & Falagas, M. E. (2004) · Critical Care · doi:10.1186/cc3020 · Cited by 209
Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa
Tam, V. H., Schilling, A. N., Vo, G., Kabbara, S., Kwa, A. L., Wiederhold, N. P., & Lewis, R. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3624-3630.2005 · Cited by 204
Landman, D., Bratu, S., Kochar, S., Panwar, M., Trehan, M., Doymaz, M., & Quale, J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm129 · Cited by 192
Self-citationKwa, A. L. H., Loh, C., Low, J. G. H., Kurup, A., & Tam, V. H. (2005) · Clinical Infectious Diseases · doi:10.1086/432583 · Cited by 191
Ouderkirk, J. P., Nord, J. A., Turett, G. S., & Kislak, J. W. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2659-2662.2003 · Cited by 188
Reina, R., Estenssoro, E., Sáenz, G., Canales, H. S., Gonzalvo, R., Vidal, G., Martins, G., Das Neves, A., Santander, O., & Ramos, C. (2005) · Intensive Care Medicine · doi:10.1007/s00134-005-2691-4 · Cited by 186
Prevention by polymyxin B of endotoxin lethality in mice
Rifkind, D. (1967) · Journal of Bacteriology · doi:10.1128/jb.93.4.1463-1464.1967 · Cited by 183
In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates
Owen, R. J., Li, J., Nation, R. L., & Spelman, D. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl512 · Cited by 176
Falagas, M. E., Kasiakou, S. K., Tsiodras, S., & Michalopoulos, A. (2006) · Clinical Medicine & Research · doi:10.3121/cmr.4.2.138 · Cited by 158
Montero, A., Ariza, J., Corbella, X., Doménech, A., Cabellos, C., Ayats, J., Tubau, F., Borraz, C., & Gudiol, F. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh485 · Cited by 158
Use of colistin in the treatment of multiple-drug-resistant gram-negative infections
Berlana, D., Llop, J. M., Casamartina, E. F., Badia, M., & Jódar, R. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.1.39 · Cited by 155
Montero, A., Ariza, J., Corbella, X., Domenech, A., Cabellos, C., Ayats, J., Tubau, F., Ardanuy, C., & Gudiol, F. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1946-1952.2002 · Cited by 151
Sobieszczyk, M. E. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh369 · Cited by 147
Me, J.-M., Pichardo-Guerrero, C., Márquez-Rivas, J., Martín-Lozano, D., Prados, T., & Pachón, J. (2002) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-001-0680-2 · Cited by 145
Bergen, P. J., Li, J., Nation, R. L., et al. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm511 · Cited by 140
Conway, S. P., Pond, M. N., Watson, A., Etherington, C., Robey, H. L., & Goldman, M. H. (1997) · Thorax · doi:10.1136/thx.52.11.987 · Cited by 136
Li, J., Rayner, C. R., Nation, R. L., Deans, R., Boots, R. J., Widdecombe, N., Douglas, A., & Lipman, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4814-4815.2005 · Cited by 133
Arroyo, L. A. R., García-Curiel, A., Pachón-Ibáñez, M. E., Llanos, A. C., Ruiz, M. T., Pachón, J., & Aznar, J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.2.903-905.2005 · Cited by 130
Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin
Tan, T. Y., & Ng, S. Y. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01708.x · Cited by 126
Song, J. Y., Kee, S. Y., Hwang, I. S., Seo, Y. B., Jeong, H. W., Kim, W. J., & Cheong, H. J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm136 · Cited by 112
Comparison of three standardized disc susceptibility testing methods for colistin
Tan, T. Y. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl330 · Cited by 100
Nicodemo, A. C., Araujo, M. R. E., Ruiz, A. S., & Gales, A. C. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh128 · Cited by 98
Nord, N. M., & Hoeprich, P. D. (1964) · New England Journal of Medicine · doi:10.1056/nejm196405142702002 · Cited by 97
Ionizing groups in lipopolysaccharides of Pseudomonas cepacia in relation to antibiotic resistance
Cox, A. D., & Wilkinson, S. G. (1991) · Molecular Microbiology · doi:10.1111/j.1365-2958.1991.tb00735.x · Cited by 96
Bronchial Constriction and Inhaled Colistin in Cystic Fibrosis
Alothman, G. A., Ho, B., Alsaadi, M. M., Ho, S. L., O'Drowsky, L., Louca, E., & Coates, A. L. (2005) · CHEST Journal · doi:10.1378/chest.127.2.522 · Cited by 92
Peterson, A. A., Fesik, S. W., & McGroarty, E. J. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.2.230 · Cited by 89
Hase, S., & Rietschel, E. (1977) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1977.tb11500.x · Cited by 85
Ventilator-associated pneumonia due to colistin susceptible-only microorganisms
Ríos, F. G., Luna, C. M., Maskin, B. C., Valiente, A., Lloria, M., Gando, S., Sosa, C., Baquero, S., Llerena, C., Petrati, C., et al. (2007) · European Respiratory Journal · doi:10.1183/09031936.00156906 · Cited by 83
Tan, T. Y., Ng, L. S. Y., Tan, E., & Huang, G. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm178 · Cited by 82
Antimicrobial Agents and the Central Nervous System
Everett, D., & Strausbaugh, L. J. (1980) · Neurosurgery · doi:10.1227/00006123-198006000-00016 · Cited by 77
Pantopoulou, A., Giamarellos‐Bourboulis, E. J., Raftogannis, M., Τσαγανός, Θ., Dontas, I. A., Koutoukas, P., Baziaka, F., Giamarellou, H., & Perrea, D. N. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.09.009 · Cited by 77
In VitroInteraction of Colistin and Rifampin on Multidrug-ResistantPseudomonas aeruginosa
Giamarellos‐Bourboulis, E. J., Sambatakou, H., Galani, I., & Giamarellou, H. (2003) · Journal of Chemotherapy · doi:10.1179/joc.2003.15.3.235 · Cited by 73
Kasiakou, S. K., Rafailidis, P. I., Liaropoulos, K., & Falagas, M. E. (2004) · Journal of Infection · doi:10.1016/j.jinf.2004.05.008 · Cited by 70
Schülin, T. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.2.403 · Cited by 70
Hoeprich, P. D. (1970) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)32591-3 · Cited by 69
Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide
Warren, H. S., Kania, S. A., & Siber, G. R. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.28.1.107 · Cited by 65
van der Heijden, I. M., Levin, A. S., Pedri, E. D., Fung, L., Rossi, F., de Almeida, G. M. D., Barone, A. A., & Costa, S. F. (2007) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-6-8 · Cited by 61
Segal‐Maurer, S., Mariano, N., Qavi, A., Urban, C. M., & Rahal, J. J. (1999) · Clinical Infectious Diseases · doi:10.1086/514754 · Cited by 60
McLeod, G., & Spector, M. P. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.13.3683-3688.1996 · Cited by 59
Conrad, R. S., & Galanos, C. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1724 · Cited by 59
Giamarellos‐Bourboulis, E. J., Karnesis, L., & Giamarellou, H. (2002) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00443-1 · Cited by 58
Cirioni, O., Ghiselli, R., Silvestri, C., Kamysz, W., Orlando, F., Mocchegiani, F., Matteo, F. D., Riva, A., Łukasiak, J., Scalise, G., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01576-06 · Cited by 53
Chemical alterations in cell envelopes of polymyxin-resistant Pseudomonas aeruginosa isolates
Gilleland, H. E., & Lyle, R. D. (1979) · Journal of Bacteriology · doi:10.1128/jb.138.3.839-845.1979 · Cited by 44
Amikacin and colistin for treatment of Acinetobacter baumannii meningitis
Fulnecky, E. J., Wright, D., Scheld, W. M., Kanawati, L., & Shoham, S. (2005) · Journal of Infection · doi:10.1016/j.jinf.2005.04.003 · Cited by 39
Jm, M., Mj, K., & Quie, P. G. (1969) · PubMed · Cited by 38
Goldstein, F. W., Ly, A., & Kitzis, M. D. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm046 · Cited by 37
Gilleland, H. E., & Farley, L. B. (1982) · Canadian Journal of Microbiology · doi:10.1139/m82-125 · Cited by 33
Kroeger, L. A., Hovde, L. B., Mitropoulos, I. F., Schafer, J. A., & Rotschafer, J. C. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01433-06 · Cited by 26
Biehl, J., & HAMBURGER, M. (1954) · A M A Archives of Internal Medicine · doi:10.1001/archinte.1954.00240270053005 · Cited by 19
Cited by
Antimicrobial Peptides: An Emerging Category of Therapeutic Agents
Mahlapuu, M., Håkansson, J., Ringstad, L., & Björn, C. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00194 · Cited by 1,927
Microbial biosurfactants production, applications and future potential
Banat, I. M., Franzetti, A., Gandolfi, I., Bestetti, G., Martinotti, M. G., Fracchia, L., Smyth, T. J., & Marchant, R. (2010) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-010-2589-0 · Cited by 1,474
Poirel, L., Jayol, A., & Nordmann, P. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00064-16 · Cited by 1,447
Antimicrobial Resistance: a One Health Perspective
McEwen, S. A., & Collignon, P. J. (2018) · Microbiology Spectrum · doi:10.1128/microbiolspec.arba-0009-2017 · Cited by 1,199
Mechanisms and consequences of bacterial resistance to antimicrobial peptides
Andersson, D. I., Hughes, D., & Kubicek-Sutherland, J. Z. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.04.002 · Cited by 715
Metadata
- Authors
- Landman, D., Georgescu, C., Martin, D. A., & Quale, J.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2008-07
- Volume
- 21
- Issue
- 3
- Pages
- 449-465
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W4211056710
- Cited by
- 565
- References
- 75
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.